Implantica AG has carried out a primary issuance of shares, represented by Swedish Depository Receipts ("SDRs"), of SEK 600 million at a subscription price of SEK 122.20 per SDR. The subscription price was determined through an accelerated bookbuilding procedure.

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Pareto Securities acted as Sole Global Coordinator and Bookrunner. Baker McKenzie acted as legal advisor to Implantica as to Swedish, Swiss and US law with an international Capital Markets team consisting of Joakim Falkner, Johanna Flink and Ian Gulam from Stockholm, Matthias Courvoisier and Beau Visser from Zurich as well as Adam Farlow and Charles Farnsworth from London.

Explore Our Newsroom